Limoges Cedex 1

• Evaluation of efficacy and tolerance of fludrocortisone (Flucortac) in the treatment of neurogenic orthostatic hypotension Recruiting
  2024-517841-16-00 6 2020-07-09 Neurogenic Orthostatic Hypotension
• First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/o … Recruiting
  2024-511862-35-00 4 2019-07-19 Adults with non-contrast-enhancing diffuse brainstem gliomas with non-
• PHASE III TRIAL INVESTIGATING BENEFIT OF INTENSIFIED PERI-OPERATIVE CHEMOTHERAPY WITHIN HIGH-RISK CINSARC PATIENTS WITH RESECTABLE SOFT-TISS … Recruiting
  2023-509489-39-00 5 2019-02-05 Resectable, non-metastatic soft-tissue sarcoma (STS)
• Trial that evaluates the interest of interruption versus maintaining the treatment of aromatase inhibitors in patients with metastatic low g … Recruiting
  2024-512629-97-00 4 2019-01-23 Patients with locally advanced or metastatic low grade endometrial str
• Avoid Anticoagulation After IntraCerebral Haemorrhage Recruiting
  2024-514094-22-00 5 2019-01-18 Intrecerebral Haemorrhage
• Paediatric Hepatic International Tumour Trial Recruiting
  2024-516110-38-00 5 2018-03-06 Hepatoblastoma and Hepatocellular Carcinoma
• CLAZI : CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections: A randomized prospective co … Recruiting
  2024-518578-15-00 5 2018-02-05 Is to demonstrate a non inferior efficacy of azithromycin and so the p
• Conservative treatment of patients with retinoblastoma Recruiting
  2024-517275-21-00 4 2012-02-20 Retinoblastoma
• Phase 3 trial aimed at improving the overall survival of AML in adults aged 18 to 60 by comparing high-dose idarubicin with daunorubicin at … Ended recruitment
  2024-516873-57-00 10 2026-01-13 Acute myeloid leukemia in adults aged 18 to 60
• A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended recruitment
  2024-520062-54-00 4 2025-07-23 Chronic Hepatitis D Virus (HDV) Infection
• BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long- Term Safety and Efficacy of Tegoprubart in Kidney … Ended recruitment
  2023-503337-21-00 4 2025-02-28 Prophylaxis of Renal Allograft Rejection
• A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL C … Ended recruitment
  2024-514032-25-00 4 2024-12-11 Patients with a histilogically confirmed diagnosis of cervical squamou
• ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia Ended recruitment
  2024-518669-83-00 4 2024-12-05 acute promyelocytic leukemia (APL) in children and adolescents
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti- … Ended recruitment
  2024-513540-29-00 5 2024-11-07 Breast Cancer
• ALS phase II study of NX210c (SEALS) Ended recruitment
  2023-508895-13-00 4 2024-10-25 Amyotrophic Lateral Sclerosis (ALS)
• Clinical trial for the treatment of COVID-19 and COVID-like illness in primary care Ended recruitment
  2022-501707-27-01 10 2024-10-03 COVID-like-illness
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended recruitment
  2023-504753-12-00 5 2024-10-01 Lung Cancer, Non-Small Cell
• A Phase 2a Study of Efinopegdutide in Adults With Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis Ended recruitment
  2024-510923-20-00 4 2024-09-16 Metabolic Dysfunction-Associated Steatohepatitis
• A phase 2 study to investigate the efficacy and safety of CYP‑001 in combination with corticosteroids in adults with high-risk acute graft v … Ended recruitment
  2022-502673-41-01 4 2024-07-29 High-Risk Acute Graft Versus Host Disease
• Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M … Ended recruitment
  2022-502975-45-00 5 2023-12-12 Metastatic leiomyosarcoma
• Treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor in mRCC patients that has … Ended recruitment
  2024-514644-93-00 5 2022-12-09 Metastatic renal cell carcinoma (mRCC) with a good or only one adverse
• A study into the efficacy and safety of dazucorilant (CORT113176) in patients with Amyotrophic Lateral Sclerosis Ended recruitment
  2024-514082-19-00 4 2022-11-04 Amyotrophic Lateral Sclerosis
• This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in … Ended recruitment
  2023-505628-67-00 5 2022-10-28 Relapsed and Refractory Follicular Lymphoma
• Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence Ended recruitment
  2024-514480-26-00 4 2022-10-12 Post-menopausal women with localized luminal A breast cancer and consi

Showing 97–120 of 190 trials